142 related articles for article (PubMed ID: 25102761)
1. TP53 in the UV spotlight: a bona fide driver of melanoma.
Hurlstone A; Wellbrock C
Pigment Cell Melanoma Res; 2014 Nov; 27(6):1010-1. PubMed ID: 25102761
[No Abstract] [Full Text] [Related]
2. UV and melanoma: the TP53 link.
Choi YS; Fisher DE
Cell Res; 2014 Oct; 24(10):1157-8. PubMed ID: 25033756
[TBL] [Abstract][Full Text] [Related]
3. Ultraviolet radiation accelerates BRAF-driven melanomagenesis by targeting TP53.
Viros A; Sanchez-Laorden B; Pedersen M; Furney SJ; Rae J; Hogan K; Ejiama S; Girotti MR; Cook M; Dhomen N; Marais R
Nature; 2014 Jul; 511(7510):478-482. PubMed ID: 24919155
[TBL] [Abstract][Full Text] [Related]
4. [Role of MBD4 in hypermutator phenotype and malignant transformation].
Rodrigues M; Mobuchon L; Houy A; Derrien AC; Fiévet A; Stern MH
Med Sci (Paris); 2018 Nov; 34(11):925-927. PubMed ID: 30526825
[No Abstract] [Full Text] [Related]
5. P53 protein and pathogenesis of melanoma and nonmelanoma skin cancer.
Benjamin CL; Melnikova VO; Ananthaswamy HN
Adv Exp Med Biol; 2008; 624():265-82. PubMed ID: 18348463
[TBL] [Abstract][Full Text] [Related]
6. Ppp6c haploinsufficiency accelerates UV-induced BRAF(V600E)-initiated melanomagenesis.
Kanazawa K; Kishimoto K; Nomura M; Kurosawa K; Kato H; Inoue Y; Miura K; Fukui K; Yamashita Y; Sato I; Tsuji H; Watanabe T; Tanaka T; Yasuda J; Tanuma N; Shima H
Cancer Sci; 2021 Jun; 112(6):2233-2244. PubMed ID: 33743547
[TBL] [Abstract][Full Text] [Related]
7. Driver mutations in melanoma: lessons learned from bench-to-bedside studies.
Mehnert JM; Kluger HM
Curr Oncol Rep; 2012 Oct; 14(5):449-57. PubMed ID: 22723080
[TBL] [Abstract][Full Text] [Related]
8. [MAP-Kinase pathway abnormalities in melanoma: B-RAF is not the sole cause].
Dereure O
Ann Dermatol Venereol; 2012 Oct; 139(10):691-2. PubMed ID: 23122387
[No Abstract] [Full Text] [Related]
9. UVB mutagenesis differs in
Bowman RL; Hennessey RC; Weiss TJ; Tallman DA; Crawford ER; Murphy BM; Webb A; Zhang S; La Perle KM; Burd CJ; Levine RL; Shain AH; Burd CE
Life Sci Alliance; 2021 Sep; 4(9):. PubMed ID: 34210801
[No Abstract] [Full Text] [Related]
10. Whole-genome landscapes of major melanoma subtypes.
Hayward NK; Wilmott JS; Waddell N; Johansson PA; Field MA; Nones K; Patch AM; Kakavand H; Alexandrov LB; Burke H; Jakrot V; Kazakoff S; Holmes O; Leonard C; Sabarinathan R; Mularoni L; Wood S; Xu Q; Waddell N; Tembe V; Pupo GM; De Paoli-Iseppi R; Vilain RE; Shang P; Lau LMS; Dagg RA; Schramm SJ; Pritchard A; Dutton-Regester K; Newell F; Fitzgerald A; Shang CA; Grimmond SM; Pickett HA; Yang JY; Stretch JR; Behren A; Kefford RF; Hersey P; Long GV; Cebon J; Shackleton M; Spillane AJ; Saw RPM; López-Bigas N; Pearson JV; Thompson JF; Scolyer RA; Mann GJ
Nature; 2017 May; 545(7653):175-180. PubMed ID: 28467829
[TBL] [Abstract][Full Text] [Related]
11. FOXD3 is a mutant B-RAF-regulated inhibitor of G(1)-S progression in melanoma cells.
Abel EV; Aplin AE
Cancer Res; 2010 Apr; 70(7):2891-900. PubMed ID: 20332228
[TBL] [Abstract][Full Text] [Related]
12. The role of BRAF mutation and p53 inactivation during transformation of a subpopulation of primary human melanocytes.
Yu H; McDaid R; Lee J; Possik P; Li L; Kumar SM; Elder DE; Van Belle P; Gimotty P; Guerra M; Hammond R; Nathanson KL; Dalla Palma M; Herlyn M; Xu X
Am J Pathol; 2009 Jun; 174(6):2367-77. PubMed ID: 19389934
[TBL] [Abstract][Full Text] [Related]
13. Sunlight ultraviolet irradiation and BRAF V600 mutagenesis in human melanoma.
Besaratinia A; Pfeifer GP
Hum Mutat; 2008 Aug; 29(8):983-91. PubMed ID: 18421705
[TBL] [Abstract][Full Text] [Related]
14. The oncogenic B-raf V599E mutation occurs more frequently in melanomas at sun-protected body sites.
Deichmann M; Krahl D; Thome M; Wüst K; Hassanzadeh J; Helmke B
Int J Oncol; 2006 Jul; 29(1):139-45. PubMed ID: 16773193
[TBL] [Abstract][Full Text] [Related]
15. A landscape of driver mutations in melanoma.
Hodis E; Watson IR; Kryukov GV; Arold ST; Imielinski M; Theurillat JP; Nickerson E; Auclair D; Li L; Place C; Dicara D; Ramos AH; Lawrence MS; Cibulskis K; Sivachenko A; Voet D; Saksena G; Stransky N; Onofrio RC; Winckler W; Ardlie K; Wagle N; Wargo J; Chong K; Morton DL; Stemke-Hale K; Chen G; Noble M; Meyerson M; Ladbury JE; Davies MA; Gershenwald JE; Wagner SN; Hoon DS; Schadendorf D; Lander ES; Gabriel SB; Getz G; Garraway LA; Chin L
Cell; 2012 Jul; 150(2):251-63. PubMed ID: 22817889
[TBL] [Abstract][Full Text] [Related]
16. Recent progress in understanding the pathology of malignant melanoma.
Kuphal S; Bosserhoff A
J Pathol; 2009 Dec; 219(4):400-9. PubMed ID: 19771562
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathological features and clinical outcomes associated with TP53 and BRAF
Kim DW; Haydu LE; Joon AY; Bassett RL; Siroy AE; Tetzlaff MT; Routbort MJ; Amaria RN; Wargo JA; McQuade JL; Kemnade J; Hwu P; Woodman SE; Roszik J; Kim KB; Gershenwald JE; Lazar AJ; Davies MA
Cancer; 2017 Apr; 123(8):1372-1381. PubMed ID: 27911979
[TBL] [Abstract][Full Text] [Related]
18. Loss of ARF sensitizes transgenic BRAFV600E mice to UV-induced melanoma via suppression of XPC.
Luo C; Sheng J; Hu MG; Haluska FG; Cui R; Xu Z; Tsichlis PN; Hu GF; Hinds PW
Cancer Res; 2013 Jul; 73(14):4337-48. PubMed ID: 23650282
[TBL] [Abstract][Full Text] [Related]
19. Human cutaneous melanoma; a review of NRAS and BRAF mutation frequencies in relation to histogenetic subclass and body site.
Platz A; Egyhazi S; Ringborg U; Hansson J
Mol Oncol; 2008 Apr; 1(4):395-405. PubMed ID: 19383313
[TBL] [Abstract][Full Text] [Related]
20. Telomere dysfunction in Tert knockout mice delays Braf
Zhang J; Zhang F; Porter KI; Dakup PP; Wang S; Robertson GP; Gaddameedhi S; Zhu J
Int J Cancer; 2024 Feb; 154(3):548-560. PubMed ID: 37727982
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
